共查询到20条相似文献,搜索用时 15 毫秒
1.
Insufficient reduction in heart rate during hospitalization despite beta‐blocker treatment in acute decompensated heart failure: insights from the ASCEND‐HF trial 下载免费PDF全文
Takeshi Kitai Justin L. Grodin Robert J. Mentz Adrian F. Hernandez Javed Butler Marco Metra John J. McMurray Paul W. Armstrong Randall C. Starling Christopher M. O'Connor Karl Swedberg W.H. Wilson Tang 《European journal of heart failure》2017,19(2):241-249
2.
3.
4.
5.
6.
David P. Kao Gordon Davis Ryan Aleong Christopher M. O'Connor Mona Fiuzat Peter E. Carson Inder S. Anand Jonathan F. Plehn Stephen S. Gottlieb Marc A. Silver JoAnn Lindenfeld Alan B. Miller Michel White Guinevere A. Murphy Will Sauer Michael R. Bristow 《European journal of heart failure》2013,15(3):324-333
7.
8.
Weir RA McMurray JJ Puu M Solomon SD Olofsson B Granger CB Yusuf S Michelson EL Swedberg K Pfeffer MA;CHARM Investigators 《European journal of heart failure》2008,10(2):157-163
BACKGROUND: The efficacy and safety of adding an angiotensin receptor blocker (ARB) in heart failure (HF) patients already taking an angiotensin-converting enzyme-inhibitor (ACE-I) plus an aldosterone antagonist is uncertain (especially if taking a beta blocker as well). The CHARM-Added trial describes the largest experience of using multiple inhibitors of the renin-angiotensin-aldosterone system (RAAS) together. METHODS AND RESULTS: 2548 HF patients, taking an ACE-I (936 no spironolactone/no beta blocker; 1175 no spironolactone/beta blocker; 199 spironolactone/no beta blocker; 238 sprionolactone/beta blocker), were randomized to placebo or candesartan and followed for 41 months (median). The primary outcome was cardiovascular death or HF hospitalization. In patients taking both a beta blocker and spironolactone (in addition to an ACE-I) at baseline, the candesartan:placebo hazard ratio was 0.85(95% CI 0.56, 1.29), compared to 0.85(95% CI 0.75, 0.96) in all randomized patients (interaction p value 0.49). The relative risk of discontinuation of candesartan (compared to placebo) because of hypotension, increased serum creatinine or hyperkalemia was not increased in patients taking spironolactone at baseline. CONCLUSIONS: An ARB may provide added benefit, at acceptable risk, in HF patients already taking spironolactone as well as an ACE-I and beta blocker. These findings must be confirmed in a prospective randomized trial before this approach can be recommended, routinely. 相似文献
9.
10.
11.
Düngen HD Apostolovic S Inkrot S Tahirovic E Töpper A Mehrhof F Prettin C Putnikovic B Neskovic AN Krotin M Sakac D Lainscak M Edelmann F Wachter R Rau T Eschenhagen T Doehner W Anker SD Waagstein F Herrmann-Lingen C Gelbrich G Dietz R;CIBIS-ELD investigators Project Multicentre Trials in the Competence Network Heart Failure 《European journal of heart failure》2011,13(6):670-680
12.
13.
The role for beta blockers in advanced heart failure (New York Heart Association class IV) remains undefined because of concerns about tolerability and uncertainty about efficacy. We report the use of a short-acting intravenous beta blocker in combination with inotropic therapy as a means to bridge five patients with advanced heart failure to chronic oral beta blockade; two of these patients had been chronically managed with intravenous inotrope. At 4 months' follow-up, all patients remained on beta-blocker therapy and none was hospitalized for heart failure or had received intravenous diuretics. Given the early separation of survival curves in the randomized clinical trials of beta blockers in heart failure, it is possible that these patients will accrue a survival benefit. We conclude that some patients with advanced heart failure can be offered oral beta-blocker therapy by bridging with a combination of intravenous inotrope and short-acting intravenous beta blocker. 相似文献
14.
Circulating microRNA‐132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure 下载免费PDF全文
Julia Beermann Christian Bär Angelika Pfanne Sabrina Thum Michela Magnoli Giovanna Balconi Gian Luigi Nicolosi Luigi Tavazzi Roberto Latini Thomas Thum 《European journal of heart failure》2018,20(1):78-85
15.
The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets 下载免费PDF全文
Sameer Zaman Saman S. Zaman Timothy Scholtes Matthew J. Shun‐Shin Carla M. Plymen Darrel P. Francis Graham D. Cole 《European journal of heart failure》2017,19(11):1401-1409
16.
17.
Wouter Ouwerkerk Tiew‐Hwa K. Teng Jasper Tromp Wan Ting Tay John G. Cleland Dirk J. van Veldhuisen Kenneth Dickstein Leong L. Ng Chim C. Lang Stefan D. Anker Faiez Zannad Chung‐Lieh Hung Jitendra P.S. Sawhney Ajay Naik Wataru Shimizu Nobuhisa Hagiwara Gurpreet Singh Wander Inder Anand A. Mark Richards Adriaan A. Voors Carolyn S.P. Lam 《European journal of heart failure》2020,22(8):1472-1482
18.
19.
Relationship between heart failure,concurrent chronic obstructive pulmonary disease and beta‐blocker use: a Danish nationwide cohort study 下载免费PDF全文
Maurizio Sessa Annamaria Mascolo Rikke Nørmark Mortensen Mikkel Porsborg Andersen Giuseppe Massimo Claudio Rosano Annalisa Capuano Francesco Rossi Gunnar Gislason Henrik Enghusen‐Poulsen Christian Torp‐Pedersen 《European journal of heart failure》2018,20(3):548-556
20.
The effect of ibopamine and furosemide in 130 patients with NYHA Class I and II heart failure were studied in a parallel, double-blind, randomized placebo-controlled multi-centre trial. Ibopamine 200 mg b.i.d. was compared to furosemide 40 mg q.d. and placebo. A 1- to 2-week single-blind run-in period was followed by an 8-week double-blind treatment period. Reproducible treadmill exercise test times with the modified Naughton-Balke protocol were required for randomization. Exercise times increased significantly in comparison to the placebo group after 8 weeks of therapy for both the furosemide group (1.2 min, P < 0.035) and the ibopamine group (1.3 min, P < 0.025). Neither furosemide nor ibopamine affected quality of life assessments. Adverse clinical experiences were generally mild and similar in frequency amongst the three treatment groups. The results of this study show the usefulness of both ibopamine and furosemide as monotherapy in patients with mild congestive heart failure. 相似文献